Trials / Completed
CompletedNCT00306254
Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery
A Phase 2B, Randomized, Multicenter, Dose-Ranging Study Assessing the Safety and Efficacy of PD 0348292 in the Prevention of Venous Thromboembolic Events (VTE) in Subjects Undergoing an Elective, Unilateral Total Knee Replacement
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,225 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To study the safety and effectiveness of several doses of PD 0348292 compared to enoxaparin in preventing blood clots in the lungs or deep leg veins of patients after knee surgery
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PD 0348292 | |
| DRUG | Enoxaparin |
Timeline
- Start date
- 2006-03-01
- Completion
- 2007-07-01
- First posted
- 2006-03-23
- Last updated
- 2007-10-10
Locations
134 sites across 16 countries: United States, Australia, Canada, Chile, Colombia, Czechia, Denmark, France, Italy, Poland, Portugal, Russia, Slovakia, South Africa, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00306254. Inclusion in this directory is not an endorsement.